RCM / R1 RCM Inc. - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-34746 R1 RCM Holdco Inc.* (Exact name of registrant as specified in its

Employment Agreement, dated June 21, 2022, by and between the Company and Lee Rivas

Exhibit 10. 2 R1 RCM Inc. Lee Rivas [***] Re: Employment Terms Dear Lee, On behalf of R1 RCM, Inc. (?R1?), I am delighted to confirm that, contingent upon the close of the transaction (?Close?) between R1 and CloudMed (?CloudMed?) you will join R1 as President, reporting to CEO Joe Flannagan. The terms and conditions of your employment with R1 are set forth in further detail below and Exhibit A (c

Form of RSU Award Agreement under R1 RCM Inc. 2022 Inducement Plan

Exhibit 10.6 GRANT OF RESTRICTED STOCK UNITS PURSUANT TO THE R1 RCM INC. 2022 INDUCEMENT PLAN * * * * * Participant: ###PARTICIPANTNAME### Grant Date: ###GRANTDATE### Number of Restricted Stock Units Granted: ###TOTALAWARDS### * * * * * THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this ?Agreement?), dated as of the Grant Date specified above, is entered into by and between R1 RCM Inc., a corporatio

Form of Pull-forward PBRSU Award Agreement under R1 RCM Inc. 2022 Inducement Plan

Exhibit 10.5 GRANT OF PERFORMANCE BASED AWARDS PURSUANT TO THE R1 RCM INC. 2022 INDUCEMENT PLAN * * * * * Participant: [NAME] Grant Date: [GRANT DATE] Number of PBRSUs: [NUMBER OF PBRSUs] Measurement Date: [MEASUREMENT DATE] (the ?Non-COC Measurement Date?) * * * * * THIS GRANT OF PERFORMANCE BASED AWARDS (this ?Agreement?), dated as of the Grant Date specified above, is entered into by and betwee

Warrant Assignment and Assumption Agreement, dated June 21, 2022, by and between the Company and TCP ASC ACHI Series LLLP

Exhibit 4.6 WARRANT ASSIGNMENT AND ASSUMPTION AGREEMENT THIS WARRANT ASSIGNMENT AND ASSUMPTION AGREEMENT (this ?Agreement?) is entered into and effective as of June 21, 2022 by and among R1 RCM Holdco Inc., a Delaware corporation (f/k/a R1 RCM Inc.; f/k/a Accretive Health, Inc.) (?Old R1 RCM?), R1 RCM Inc., a Delaware corporation (f/k/a Project Roadrunner Parent Inc.) (?New R1 RCM?), and TCP-ASC A

R1 RCM Inc. 2022 Inducement Plan

Exhibit 10.3 R1 RCM INC. 2022 INDUCEMENT PLAN 1. Purpose. This R1 RCM Inc. 2022 Inducement Plan (the ?Plan?) of R1 RCM Inc., a Delaware corporation formerly known as Project Roadrunner Parent Inc. (the ?Company?), is effective as of June 21, 2022 (the ?Effective Date?). The purpose of the Plan is to advance the interests of the Company?s stockholders by allowing the Company to secure and retain th

Changes in Control of Registrant, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 R1 RCM Holdco Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

R1 RCM Completes Acquisition of Cloudmed Combined company to deliver a scalable, flexible, and integrated platform to optimize revenue cycle and consumer engagement in healthcare R1 to Host Conference Call on June 27 at 4:30pm ET

Exhibit 99.2 R1 RCM Completes Acquisition of Cloudmed Combined company to deliver a scalable, flexible, and integrated platform to optimize revenue cycle and consumer engagement in healthcare R1 to Host Conference Call on June 27 at 4:30pm ET MURRAY, Utah, June 21, 2022 ? R1 RCM Inc. (NASDAQ: RCM) (?R1?), a leading provider of technology-driven solutions that transform the patient experience and f

Amended and Restated Investor Rights Agreement, dated June 21, 2022, by and among the Company, Old R1 RCM and TCP-ASC ACHI Series LLLP

Exhibit 4.2 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT Amended and Restated Investor Rights Agreement, dated as of June 21, 2022 (this ?Agreement?), by and among R1 RCM Inc., a Delaware corporation (the ?Company?), R1 RCM Holdco Inc. (formerly known as R1 RCM Inc. and Accretive Health, Inc.), a Delaware corporation (?Former Pubco?), TCP-ASC ACHI Series LLLP, a Delaware limited liability limite

As filed with the Securities and Exchange Commission on June 21, 2022

As filed with the Securities and Exchange Commission on June 21, 2022 Registration Statement File No.

Form of Standard PBRSU Award Agreement under R1 RCM Inc. 2022 Inducement Plan

Exhibit 10.4 GRANT OF PERFORMANCE BASED AWARDS PURSUANT TO THE R1 RCM INC. 2022 INDUCEMENT PLAN * * * * * Participant: Grant Date: Number of PBRSUs: Measurement Date: [NAME] [GRANT DATE] [NUMBER OF PBRSUs] [MEASUREMENT DATE] (the ?Non-COC Measurement Date?) * * * * * THIS GRANT OF PERFORMANCE BASED AWARDS (this ?Agreement?), dated as of the Grant Date specified above, is entered into by and betwee

Second Amended and Restated Credit Agreement, dated June 21, 2022, by and among Old R1 RCM Inc., as the Initial Borrower), the Company, as the Ultimate Borrower, the other Persons party thereto that are designated as a “Credit Party”, Bank of America, N.A., as Agent for the several financial institutions from time to time party thereto and the Lenders

Exhibit 10.1 Execution Version Deal CUSIP: 74919EAK0 Revolving Loan CUSIP: 74919EAL8 Initial Term A Loan CUSIP: 74919EAM6 Incremental Term A Loan CUSIP: 74919EAN4 Initial Term B Loan CUSIP: 74919EAP9 SECOND AMENDED AND RESTATED CREDIT AGREEMENT Dated as of June 21, 2022 by and among R1 RCM HOLDCO INC. (formerly R1 RCM INC.), as the Initial Borrower, R1 RCM INC. (formerly PROJECT ROADRUNNER PARENT,

Investor Rights Agreement, dated June 21, 2022, by and among the Company and the Sellers

Exhibit 4.3 INVESTOR RIGHTS AGREEMENT Investor Rights Agreement, dated as of June 21, 2022 (this ?Agreement?), by and among R1 RCM Inc., a Delaware corporation (the ?Company?), CoyCo 1, L.P., a Delaware limited partnership (?Coyco 1?), and Coyco 2, L.P., a Delaware limited partnership (?Coyco 2?, each of Coyco 1 and Coyco 2, an ?Investor? and collectively, the ?Investors?), and, solely for purpose

As filed with the Securities and Exchange Commission on June 21, 2022

As filed with the Securities and Exchange Commission on June 21, 2022 Registration Statement File No.

As filed with the Securities and Exchange Commission on June 21, 2022

As filed with the Securities and Exchange Commission on June 21, 2022 Registration Statement File No.

As filed with the Securities and Exchange Commission on June 21, 2022

As filed with the Securities and Exchange Commission on June 21, 2022 Registration Statement File No.

2

Exhibit 99.1 R1 Announces Grants of Inducement Equity Awards in Connection with the Acquisition of Cloudmed 06/21/22 MURRAY, Utah, June 21, 2022 (GLOBE NEWSWIRE) ? R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance for healthcare providers, today announced that it has granted equity awards under the R1 RCM Inc

RCM / R1 RCM Inc / TCP-ASC ACHI Series LLLP - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 14)* R1 RCM Holdco Inc. (f/k/a R1 RCM INC.) (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00438V103 (CUSIP Number) Glenn Miller c/o TowerBrook Capital Partners L.P. Park Avenue Tower 65 East 55th Street, 19th Floor N

As filed with the Securities and Exchange Commission on June 21, 2022

As filed with the Securities and Exchange Commission on June 21, 2022 Registration Statement File No.

Amendment to the Old R1 RCM Charter

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF R1 RCM INC. R1 RCM Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY AS FOLLOWS: FIRST: The Restated Certificate of Incorporation of the Corporation is hereby amended by deleting the first paragraph of Article

Amended and Restated Bylaws of the Company

Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF R1 RCM INC. (F/K/A PROJECT ROADRUNNER PARENT INC.) Adopted June 21, 2022 TABLE OF CONTENTS ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 2 1.10 Nomination of Directors 3 1.11 Notice of Bus

Amended and Restated Certificate of Incorporation of the Company

Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF R1 RCM INC. FIRST: The name of the Corporation is R1 RCM Inc. SECOND: The address of the Corporation?s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle 19801. The name of its registered agent at that address is The Corporation Trust Company. TH

Warrant Assignment and Assumption Agreement, dated June 21, 2022, by and between the Company and IHC Health Services, Inc.

Exhibit 4.4 WARRANT ASSIGNMENT AND ASSUMPTION AGREEMENT THIS WARRANT ASSIGNMENT AND ASSUMPTION AGREEMENT (this ?Agreement?) is entered into and effective as of June 21, 2022 by and among R1 RCM Holdco Inc., a Delaware corporation (f/k/a R1 RCM Inc.; f/k/a Accretive Health, Inc.) (?Old R1 RCM?), R1 RCM Inc., a Delaware corporation (f/k/a Project Roadrunner Parent Inc.) (?New R1 RCM?), and IHC Healt

Second Amended and Restated Registration Rights Agreement, dated as of June 21, 2022, by and among the Company, Old R1 RCM, TCP-ASC ACHI Series LLLP, IHC Health Services, Inc., Shared Business Services, LLC and the Sellers

Exhibit 4.1 SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT Second Amended and Restated Registration Rights Agreement (this ?Agreement?), dated as of June 21, 2022, by and among R1 RCM Inc., a Delaware corporation (the ?Company?), R1 RCM Holdco Inc. (formerly known as R1 RCM Inc.), a Delaware corporation and wholly-owned subsidiary of the Company (?Former Pubco?), TCP-ASC ACHI Series LLL

Form of Grant of Performance Based Restricted Stock Unit Awards under the R1 RCM Inc. Third Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No. 001-34746) filed on June 14, 2022)

Exhibit 10.1 Standard Award GRANT OF PERFORMANCE BASED AWARDS PURSUANT TO THE R1 RCM INC. THIRD AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN * * * * * Participant: [NAME] Grant Date: [GRANT DATE] Number of PBRSUs: [NUMBER OF PBRSUs] Measurement Date: [MEASUREMENT DATE] (the ?Non-COC Measurement Date?) * * * * * THIS GRANT OF PERFORMANCE BASED AWARDS (this ?Agreement?), dated as of the Grant Date

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Form of Grant of Performance Based Restricted Stock Unit Awards (Pull-forward) under the R1 RCM Inc. Third Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K (File No. 001-34746) filed on June 14, 2022)

Exhibit 10.2 Pull-Forward Award GRANT OF PERFORMANCE BASED AWARDS PURSUANT TO THE R1 RCM INC. THIRD AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN * * * * * Participant: [NAME] Grant Date: [GRANT DATE] Number of PBRSUs: [NUMBER OF PBRSUs] Measurement Date: [MEASUREMENT DATE] (the ?Non-COC Measurement Date?) * * * * * THIS GRANT OF PERFORMANCE BASED AWARDS (this ?Agreement?), dated as of the Grant

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

R1 RCM Presentation at the 2022 RBC Capital Markets Global Healthcare Conference May 17, 2022

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 Commission File No. for the Related Registration Statement: 333-264188 Date: May 17, 2022 The following is a complete transcript of R1 RCM Inc.?s fireside ch

R1 RCM Presentation at the Bank of America Securities 2022 Healthcare Conference May 11, 2022

425 1 a5112022boatranscript.htm 425 Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 Commission File No. for the Related Registration Statement: 333-264188 Date: May 12, 2022 The following is a complete tra

R1 RCM Reports First Quarter 2022 Results

Exhibit 99.1 R1 RCM Reports First Quarter 2022 Results Murray, Utah - May 9, 2022 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended March 31, 2022. First Quarter 2022 Results: ?Revenue of $385.7 million, up $43.1 million or 12.6% c

May 9, 2022 First Quarter 2022 Earnings Call NEED NEW IMAGE THAT WE SENT Exhibit 99.2 2 Forward-Looking Statements This presentation includes information that may constitute “forward-looking statements” made pursuant to the safe harbor provisions of

May 9, 2022 First Quarter 2022 Earnings Call NEED NEW IMAGE THAT WE SENT Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-34746 R1 RCM IN

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 R1 RCM Inc. (Exact Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

Proxy Statement/Prospectus

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a

R1 RCM Cloudmed Teach-In April 12, 2022

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 Commission File No. for the Related Registration Statement: 333-264188 Date: April 13, 2022 The following is a complete transcript of R1 RCM Inc.'s teach-in

1 Since announcing the acquisition of Cloudmed I have grown even more excited about the great future we anticipate together... From the Desk of Joe Flanagan, President, and CEO R1 Team, Since announcing the acquisition of Cloudmed I have grown even m

1 Since announcing the acquisition of Cloudmed I have grown even more excited about the great future we anticipate together.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

1 I am thrilled to return to R1 as Executive Vice President of Integration. When I think about the value of the Cloudmed integration... From the Desk of Wes Arnett, EVP, Integration R1 team, I am thrilled to return to R1 as Executive Vice President o

1 I am thrilled to return to R1 as Executive Vice President of Integration. When I think about the value of the Cloudmed integration... From the Desk of Wes Arnett, EVP, Integration R1 team, I am thrilled to return to R1 as Executive Vice President of Integration. When I think about the value of the Cloudmed integration, it?s all about growth, and accelerating our growth as a combined company. Thi

R1 RCM Announces Filing of Registration Statement on Form S-4 Related to Proposed Acquisition of Cloudmed

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 Date: April 8, 2022 R1 RCM Announces Filing of Registration Statement on Form S-4 Related to Proposed Acquisition of Cloudmed Murray, Utah – April 7, 2022 -

R1 RCM Presentation at the Barclays Global Healthcare Conference March 16, 2022

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 Date: March 16, 2022 The following is a complete transcript of R1 RCM Inc.?s fireside chat held on March 16, 2022 at the Barclays Global Healthcare Conferenc

R1 RCM Presentation at the 42nd Annual Cowen Health Care Conference March 8, 2022

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 Date: March 8, 2022 The following is a complete transcript of R1 RCM Inc.?s fireside chat held on March 8, 2022 at the 42nd Annual Cowen Health Care Conferen

R1 RCM Presentation at SVB Leerink 11th Annual Global Healthcare Conference February 18, 2022

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 Date: February 18, 2022 The following is a complete transcript of R1 RCM Inc.?s fireside chat and corresponding presentation held on February 18, 2022 at the

R1 RCM Fourth Quarter 2021 Earnings Call February 17, 2022

425 1 a2172022earningscalltransc.htm 425 Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 Date: February 17, 2022 The following is a complete transcript of R1 RCM Inc.’s earnings call held on February 17, 2

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of R1 RCM Inc. Subsidiary Jurisdiction of Organization Accretive Health Mauritius, Inc. Mauritius cGate Health, Inc. Delaware Clearsight Intermediate Holdings, Inc. Delaware Flare Capital Partners Investment Company Delaware Intermedix ARM, LLC Delaware Intermedix Corporation Delaware Intermedix Holdings, Inc. Delaware Intermedix Lietuva, UAB Lithuania Intermedix Midco, I

• January 10, 2022February 17, 2 22 Fourth Quarter and Full Year 2021 Earnings Call NEED NEW IMAGE THAT WE SENT Exhibit 99.2 2 Forward-Looking Statements This presentation includes information that may constitute “forward-looking statements,” made pu

? January 10, 2022February 17, 2 22 Fourth Quarter and Full Year 2021 Earnings Call NEED NEW IMAGE THAT WE SENT Exhibit 99.

Offer Letter, dated September 27, 2019, between Registrant and Vijay Kotte

Exhibit 10.62 R1 RCM Inc. 401 N Michigan Avenue, Suite 2700 Chicago, IL 60611 September 27, 2019 Re: Employment Terms Dear Vijay, On behalf of R1 RCM, I am delighted to confirm our offer to you to join R1 as Executive Vice President, Physician Services, reporting to the Chief Executive Officer. Your start date will be Monday October 14, 2019. Salary and Annual Bonus Your starting salary will be $5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 R1 RCM Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34746 R1 RCM Inc. (Exact name of

R1 RCM Reports Fourth Quarter and Full Year 2021 Results

Exhibit 99.1 R1 RCM Reports Fourth Quarter and Full Year 2021 Results Murray, Utah - February 17, 2022 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months and year ended December 31, 2021. Fourth Quarter 2021 Results: ?Revenue of $398.9 mi

RCM / R1 RCM Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: R1 RCM Inc. Title of Class of Securities: Common Stock CUSIP Number: 749397105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13

R1 Announces Alex Mandl Will Not Stand for Re-Election to R1 Board of Directors

Exhibit 99.1 R1 Announces Alex Mandl Will Not Stand for Re-Election to R1 Board of Directors MURRAY, UT ? February 7, 2022 ? R1 RCM Inc. (NASDAQ: RCM) (?R1?), today announced that Alex Mandl informed the company he will not stand for re-election to the R1 board of directors at its next annual meeting of stockholders. Mr. Mandl was elected to the R1 board of directors in 2013 and has served as lead

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

1 JANUARY 18, 2022 The Strategic Partner to the Provider Industry The fol lowing s l ide presentat ion , or port ions thereof , was created to be used in customer and prospect conversat ions on or af ter January 18, 2022. Fi led by R1 RCM Inc. Pursua

425 1 a4251-18x2022acquisition.htm 425 1 JANUARY 18, 2022 The Strategic Partner to the Provider Industry The fol lowing s l ide presentat ion , or port ions thereof , was created to be used in customer and prospect conversat ions on or af ter January 18, 2022. Fi led by R1 RCM Inc. Pursuant to Rule 425 under the Securi t ies Act of 1933, as amended, and deemed f i led pursuant to Rule 14a-12 under

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 20

425 1 d268801d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2022 R1 RCM Inc. (Exact name of registrant as specified in its charter) Delaware 001-34746 02-0698101 (State or other jurisdic

Filed by R1 RCM Inc.

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001- 34746 The following document was sent to all customers of R1 RCM on January 10, 2022. 1. What was announced? ? R1 announced that it has entered into a definitive

RCM / R1 RCM Inc / TCP-ASC ACHI Series LLLP - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 13)* R1 RCM INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00438V103 (CUSIP Number) Glenn Miller c/o TowerBrook Capital Partners L.P. Park Avenue Tower 65 East 55th Street, 19th Floor New York, NY 10022 (212) 699

Filed by R1 RCM Inc.

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 The following talking points were distributed to associates of R1 RCM on January 10, 2022 to use in conversations with vendors and business partners relating

Filed by R1 RCM Inc.

425 1 d270338d425.htm 425 Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 JANUARY 10, 2022 / 4:15PM, RCM.OQ - R1 RCM Inc at JPMorgan Healthcare Conference (Virtual) CORPORATE PARTICIPANTS Joseph Gerard Fla

Transaction Agreement and Plan of Merger, dated as of January 9, 2022 among Old R1 RCM, Project Roadrunner Parent Inc., Project Roadrunner Merger Sub Inc., Coyco 1, L.P., and Coyco 2, L.P. (incorporated by reference to Exhibit 2.1 to the Current Report

Exhibit 2.1 Execution Version TRANSACTION AGREEMENT AND PLAN OF MERGER Dated as of January 9, 2022 Among R1 RCM INC., PROJECT ROADRUNNER PARENT INC., PROJECT ROADRUNNER MERGER SUB INC., REVINT HOLDINGS, LLC, COYCO 1, L.P., and COYCO 2, L.P. TABLE OF CONTENTS Page ARTICLE I THE TRANSACTIONS 2 Section 1.01 The Merger 2 Section 1.02 The Contribution 2 Section 1.03 Consideration Adjustment 3 Section 1

Filed by R1 RCM Inc.

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001- 34746 The following document was sent to all employees of R1 RCM on January 10, 2022. What Was Announced • Thanks for taking the time to speak with me. • I know w

Filed by R1 RCM Inc.

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 JANUARY 10, 2022 / 12:00PM, RCM.OQ - R1 RCM Inc to Acquire CloudMed Solutions Inc Call CORPORATE PARTICIPANTS Atif A. Rahim R1 RCM Inc. - SVP of IR & Busines

The following is a transcript of a video sent to all employees of R1 RCM on January 11, 2022.

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 The following is a transcript of a video sent to all employees of R1 RCM on January 11, 2022. Joseph Gerard Flanagan - R1 RCM Inc. - President, CEO & Directo

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2022 R1 RCM Inc. (Exact name of registrant as specified in its charter) Delaware 001-34746 02-0698101 (State or other jurisdiction of incorporation) (Co

Filed by R1 RCM Inc.

425 1 d267604d425.htm 425 Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 The following social media posts were shared by R1 RCM and Cloudmed on January 10, 2022. Cloudmed Twitter We’re excited to announce

Filed by R1 RCM Inc.

425 1 d248077d425.htm 425 Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 The following letter was sent to all employees of R1 RCM on January 10, 2022. From the Desk of Joe Flanagan, CEO Subject: Exciting

Form of Investor Rights Agreement between Project Roadrunner Parent Inc., Coyco 1, L.P. and Coyco 2, L.P.

Exhibit 4.3 INVESTOR RIGHTS AGREEMENT Investor Rights Agreement, dated as of [?], 2022 (this ?Agreement?), by and among R1 RCM Inc., a Delaware corporation (the ?Company?), CoyCo 1, L.P., a Delaware limited partnership (?Coyco 1?), and Coyco 2, L.P., a Delaware limited partnership (?Coyco 2?, each of Coyco 1 and Coyco 2, an ?Investor? and collectively, the ?Investors?), and, solely for purposes of

Form of Second Amended and Restated Registration Rights Agreement between the Company, Project Roadrunner Parent Inc., TCP-ASC ACHI Series LLLP, IHC Health Services, Inc., LifePoint Health, Inc., Coyco 1, L.P. and Coyco 2, L.P.

Exhibit 4.1 SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT Second Amended and Restated Registration Rights Agreement (this ?Agreement?), dated as of [?], 2022, by and among R1 RCM Inc., a Delaware corporation (the ?Company?), [?] (formerly known as R1 RCM Inc.), a Delaware corporation and wholly-owned subsidiary of the Company (?Former Pubco?), TCP-ASC ACHI Series LLLP, a Delaware limit

Voting Agreement, dated as of January 9, 2022, between Old R1 RCM, Revint Holdings, LLC, and TCP-ASC ACHI Series LLLP (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K/A (File No. 001-34746) filed on January 11, 2022)

Exhibit 10.1 Execution Version VOTING AGREEMENT This Voting Agreement (this ?Agreement?) is made and entered into as of January 9, 2022 (the ?Agreement Date?), by and among R1 RCM Inc., a Delaware corporation (?Roadrunner?), TCP-ASC ACHI Series LLLP, a Delaware limited liability limited partnership (the ?Stockholder?), and Revint Holdings, LLC, a Delaware limited liability company (?Coyote?). Each

Form of Amended and Restated Investor Rights Agreement between the Company, Project Roadrunner Parent Inc. and TCP-ASC ACHI Series LLLP

Exhibit 4.2 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT Amended and Restated Investor Rights Agreement, dated as of [?], 2022 (this ?Agreement?), by and among R1 RCM Inc., a Delaware corporation (the ?Company?), [?] (formerly known as R1 RCM Inc. and Accretive Health, Inc.), a Delaware corporation (?Former Pubco?), TCP-ASC ACHI Series LLLP, a Delaware limited liability limited partnership (the

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2022 R1 RCM Inc. (Exact name of registrant as specified in its charter) Delaware 001-34746 02-0698101 (State or other jurisdiction of incorporation or organization) (Commiss

Filed by R1 RCM Inc.

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 The following talking points were distributed to associates of R1 RCM on January 10, 2022 to use in conversations with customers relating to R1 RCM?s propose

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2022 R1 RCM Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2022 R1 RCM Inc. (Exact name of registrant as specified in its charter) Delaware 001-34746 02-0698101 (State or other jurisdiction of incorporation or organization) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 R1 RCM Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Filed by R1 RCM Inc.

425 1 d282431d425.htm 425 Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 The following document was sent to all vendors and business partners of R1 RCM on January 10, 2022. 1. What was announced? • R1 ann

R1 RCM to Acquire Cloudmed, Creating the Strategic Revenue Partner for Healthcare Providers Advances Integrated Technology Strategy Through Enhanced Revenue Intelligence and Expanded Automation Opportunity R1 to Host Conference Call Today at 7:00 a.m

Exhibit 99.1 R1 RCM to Acquire Cloudmed, Creating the Strategic Revenue Partner for Healthcare Providers Advances Integrated Technology Strategy Through Enhanced Revenue Intelligence and Expanded Automation Opportunity R1 to Host Conference Call Today at 7:00 a.m. ET MURRAY, Utah and ATLANTA, January 10, 2022 ? R1 RCM Inc. (NASDAQ: RCM) (?R1?), a leading provider of technology-driven solutions tha

Forward-Looking Statements This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities

JANUARY 10, 2022 The Strategic Partner to the Provider Industry Exhibit 99.2 Forward-Looking Statements This presentation includes information that may constitute ?forward-looking statements,? made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally re

Filed by R1 RCM Inc.

425 1 d250368d425.htm 425 Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 The following document was sent to all vendors and business partners of R1 RCM on January 10, 2022. To [Our Valued Partner] / [INSE

• January 10, 2022JANUARY 10, 202 40th Annual J.P. Morgan Healthcare Conference NEED NEW IMAGE THAT WE SENT Exhibit 99.1 2 Forward-Looking Statements This presentation includes information that may constitute “forward-looking statements,” made pursua

? January 10, 2022JANUARY 10, 202 40th Annual J.P. Morgan Healthcare Conference NEED NEW IMAGE THAT WE SENT Exhibit 99.1 2 Forward-Looking Statements This presentation includes information that may constitute ?forward-looking statements,? made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as am

Filed by R1 RCM Inc.

425 1 d91664d425.htm 425 Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 The following document was sent to all employees of R1 RCM on January 10, 2022. 1. Why is R1 acquiring Cloudmed? Why now? • Since an

Filed by R1 RCM Inc.

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 The following letter was sent to all investor analysts of R1 RCM on January 10, 2022. Dear [NAME], R1 RCM just issued a press release announcing that it has

Filed by R1 RCM Inc.

Filed by R1 RCM Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: R1 RCM Inc. Commission File No.: 001-34746 The following letter was sent to all customers of R1 RCM on January 10, 2022. Dear [INSERT CUSTOMARY GREETING], I am pleased to share some exciting news that

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Third Quarter 2021 Results Conference Call November 2, 2021 Exhibit 99.2 2 Forward‐Looking Statements and Non‐GAAP Financial Measures This presentation includes information that may constitute “forward‐looking statements,” made pursuant to the safe h

Third Quarter 2021 Results Conference Call November 2, 2021 Exhibit 99.2 2 Forward?Looking Statements and Non?GAAP Financial Measures This presentation includes information that may constitute ?forward?looking statements,? made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward?looking statements relate to future, not past, events and often addr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-34746 R1 RC

R1 RCM Reports Third Quarter 2021 Results

Exhibit 99.1 R1 RCM Reports Third Quarter 2021 Results Murray, Utah - November 2, 2021 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2021. Third Quarter 2021 Results: ?Revenue of $379.7 million, up $72.5 million o

R1 Announces Appointment of Agnes Bundy Scanlan to Board of Directors

Exhibit 99.1 R1 Announces Appointment of Agnes Bundy Scanlan to Board of Directors Murray, UT ? August 12, 2021 ? R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the appointment of Agnes Bundy Scanlan, president of The Cambridge Group LLC, to the company?s board of

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-34746 R1 RCM INC

Amended and Restated Credit Agreement, dated as of July 1, 2021, by and among R1 RCM Inc., the other parties party thereto as Credit Parties (as defined therein), Bank of America, N.A., as administrative agent and the financial institutions party thereto as lenders

Exhibit 10.3 Execution Version $1,150,000,000 AMENDED AND RESTATED CREDIT AGREEMENT Dated as of July 1, 2021 by and among R1 RCM INC., as the Borrower, THE OTHER PERSONS PARTY HERETO THAT ARE DESIGNATED AS CREDIT PARTIES, BANK OF AMERICA, N.A., as Agent for all Lenders, THE OTHER FINANCIAL INSTITUTIONS PARTY HERETO as Lenders, and BOFA SECURITIES, INC., JPMORGAN CHASE BANK, N.A., CAPITAL ONE, N.A.

and Ascension Health effective May 1, 2021 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-34746) filed on August 3, 2021)

Exhibit 10.1 EXECUTION COPY AMENDMENT NO. 5 TO AMENDED AND RESTATED MASTER PROFESSIONAL SERVICES AGREEMENT BY AND BETWEEN ASCENSION HEALTH AND R1 RCM INC. This Amendment No. 5 to the Master Professional Services Agreement (this ?Amendment?) by and between Ascension Health (d/b/a Ascension Healthcare) (?Ascension Health?) and R1 RCM Inc. (formerly known as Accretive Health, Inc.) (?Supplier?) is en

R1 RCM Reports Second Quarter 2021 Results; Raises 2021 Guidance

Exhibit 99.1 R1 RCM Reports Second Quarter 2021 Results; Raises 2021 Guidance Murray, Utah - August 3, 2021 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended June 30, 2021. Second Quarter 2021 Results: ?Revenue of $353.4 million, u

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

Second Quarter 2021 Results Conference Call August 3, 2021 Exhibit 99.2 2 Q2 Financial Highlights and Updated 2021 Guidance Second Quarter 2021 Results  Revenue of $353.4 million, up $38.7 million or 12.3% compared to the same period last year  GAA

Second Quarter 2021 Results Conference Call August 3, 2021 Exhibit 99.2 2 Q2 Financial Highlights and Updated 2021 Guidance Second Quarter 2021 Results ? Revenue of $353.4 million, up $38.7 million or 12.3% compared to the same period last year ? GAAP net income of $18.4 million, up $3.3 million or 21.9% compared to the same period last year ? Adjusted EBITDA2 of $78.8 million, up $13.5 million or

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Amended and Restated Credit Agreement, dated as of July 1, 2021, by and among R1 RCM Inc., the other parties party thereto as Credit Parties (as defined therein), Bank of America, N.A., as administrative agent and the financial institutions party thereto as lenders.

Exhibit 10.1 Execution Version $1,150,000,000 AMENDED AND RESTATED CREDIT AGREEMENT Dated as of July 1, 2021 by and among R1 RCM INC., as the Borrower, THE OTHER PERSONS PARTY HERETO THAT ARE DESIGNATED AS CREDIT PARTIES, BANK OF AMERICA, N.A., as Agent for all Lenders, THE OTHER FINANCIAL INSTITUTIONS PARTY HERETO as Lenders, and BOFA SECURITIES, INC., JPMORGAN CHASE BANK, N.A., CAPITAL ONE, N.A.

RCM / R1 RCM Inc / TCP-ASC ACHI Series LLLP - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* R1 RCM INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00438V103 (CUSIP Number) Glenn Miller c/o TowerBrook Capital Partners L.P. Park Avenue Tower 65 East 55th Street, 27th Floor New York, NY 10022 (212) 699

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Information Relating to Part II, Item 14. Other Expenses of Issuance and Distribution.

EXHIBIT 99.1 Information Relating to Part II, Item 14. Other Expenses of Issuance and Distribution. The following is a statement of the expenses incurred or expected to be incurred, other than underwriting discounts and commissions, to be paid solely by R1 RCM Inc., in connection with the issuance and distribution of the securities being registered hereby. All expenses other than the Securities an

Underwriting Agreement, dated as of May 26, 2021, by and among the Company, the Selling Stockholders and Barclays Capital Inc. and J.P. Morgan Securities LLC, as representatives of the Underwriters.

Exhibit 1.1 R1 RCM INC. 15,000,000 Shares of Common Stock Underwriting Agreement May 26, 2021 Barclays Capital Inc. J.P. Morgan Securities LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Certain stockho

15,000,000 Shares R1 RCM Inc. Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-256465 PROSPECTUS SUPPLEMENT (To Prospectus dated May 25, 2021) 15,000,000 Shares R1 RCM Inc. Common Stock The selling stockholders identified in this prospectus supplement are offering 15,000,000 shares of our common stock. Of these shares, 14,500,000 shares are issuable upon exercise of a portion of an outstanding warrant. W

Subject to Completion, dated May 25, 2021

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256465 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities nor are they soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permit

As filed with the Securities and Exchange Commission on May 25, 2021

Table of Contents As filed with the Securities and Exchange Commission on May 25, 2021 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

As filed with the Securities and Exchange Commission on May 21, 2021

As filed with the Securities and Exchange Commission on May 21, 2021 Registration No.

PROPOSAL 2 - APPROVAL OF R1 RCM INC. THIRD AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN

Exhibit 99.1 PROPOSAL 2 - APPROVAL OF R1 RCM INC. THIRD AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN Overview of Amendment We are asking you to approve the proposed R1 RCM Inc. Third Amended and Restated 2010 Stock Incentive Plan (the ?Amended Plan?), which is an amendment and restatement of the Accretive Health, Inc. Second Amended and Restated 2010 Stock Incentive Plan (the ?2010 Plan?). Our b

R1 RCM Inc. Third Amended and Restated Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No. 001-34746) filed on May 21, 2021)

Exhibit 10.1 R1 RCM INC. THIRD AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN 1. Purpose. This Third Amended and Restated 2010 Stock Incentive Plan (the ?Plan?) of R1 RCM Inc., a Delaware corporation formerly known as Accretive Health, Inc. (the ?Company?), is effective as of March 23, 2021 (the ?Effective Date?), and amends and restates the Company?s Second Amended and Restated 2010 Stock Incenti

Investor Presentation May 17, 2021 Exhibit 99.1 2 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the P

Investor Presentation May 17, 2021 Exhibit 99.1 2 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute ?forward-looking statements,? made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past, events and often address our expected future g

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

and Joseph Flanagan dated March 23, 2021 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-34746) filed on May 4, 2021)

Exhibit 10.1 Execution Version R1 RCM INC. 401 N. Michigan Avenue Chicago, Illinois 60611 March 23, 2021 Mr. Joseph Flanagan Re: Offer Letter Dear Joe: Reference is made to the offer letter, dated April 27, 2013 (as amended as of April 29, 2014 and March 6, 2019, the ?Offer Letter?) between you and R1 RCM Inc. (previously known as Accretive Health, Inc.), a Delaware corporation (the ?Company?). Th

Addendum No. 8 to the Amended and Restated Services Agreement between the Registrant and IHC Health Services, Inc. dated as of March 24, 2021

Exhibit 10.2 ADDENDUM NO. 8 TO AMENDED AND RESTATED SERVICES AGREEMENT This Addendum No. 8 (this ?Addendum?) is made and entered into as of the 24th day of March, 2021 (the ?Addendum Effective Date?) by and between IHC Health Services, Inc., a Utah non-profit corporation, (?IMH? or sometimes referred to as ?Intermountain? or ?Intermountain Healthcare?) and R1 RCM Inc., a Delaware corporation, form

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

R1 Announces Revenue Cycle Management Partnership Expansion and Extension with Ascension R1 and Ascension to transform the consumer experience in healthcare

Exhibit 99.1 R1 Announces Revenue Cycle Management Partnership Expansion and Extension with Ascension R1 and Ascension to transform the consumer experience in healthcare CHICAGO ? May 4, 2021 ? R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced a strategic expansion an

First Quarter 2021 Results Conference Call May 4, 2021 Exhibit 99.2 2 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor

rcm1q21earningspresentat First Quarter 2021 Results Conference Call May 4, 2021 Exhibit 99.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-34746 R1 RCM IN

R1 RCM Reports First Quarter 2021 Results

Exhibit 99.1 R1 RCM Reports First Quarter 2021 Results CHICAGO - May 4, 2021 - R1 RCM Inc (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended March 31, 2021. First Quarter 2021 Results: •Revenue of $342.6 million, up $22.1 million or 6.9% compared

R1 Announces Appointment of David Dill to Board of Directors

Exhibit 99.1 R1 Announces Appointment of David Dill to Board of Directors CHICAGO ? April 19, 2021 ? R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the appointment of David Dill, president and chief executive officer of LifePoint Health, to the company?s board of d

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Old R1 RCM

Exhibit 3.1 AMENDMENT NO. 3 TO THE AMENDED AND RESTATED BYLAWS OF R1 RCM INC. THIS AMENDMENT NO. 3 TO THE AMENDED AND RESTATED BYLAWS of R1 RCM Inc. (f/k/a Accretive Health, Inc.), a Delaware corporation (the ?Bylaws?), is made as of this 23rd day of February, 2021. 1. In accordance with Article VI of the Amended and Restated Bylaws, as amended (the ?Bylaws?) of R1 RCM Inc., a Delaware corporation

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34746 R1 RCM Inc. (Exact name of

R1 RCM Reports Fourth Quarter and Full Year 2020 Results

Exhibit 99.1 R1 RCM Reports Fourth Quarter and Full Year 2020 Results CHICAGO - February 18, 2021 - R1 RCM Inc (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months and year ended December 31, 2020. Fourth Quarter 2020 Results: •Revenue of $328.4 million,

’s Second Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.71 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (File No. 001-34746) filed on February 18, 2021)

Exhibit 10.71 GRANT OF RESTRICTED STOCK UNITS PURSUANT TO THE R1 RCM INC. SECOND AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN * * * * * Participant: [ ] Grant Date: [ ] Number of Restricted Stock Units Granted: [ ] * * * * * THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this ?Agreement?), dated as of the Grant Date specified above, is entered into by and between R1 RCM Inc., a corporation organize

Joinder and Amendment to the Amended and Restated Registration Rights Agreement, dated as of January 23, 2018, by and among the Registrant, TCP-ASC ACHI Series LLLP, and Shared Business Services, LLC

Exhibit 10.70 Execution Version JOINDER AND AMENDMENT TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT January 22, 2021 The undersigned is executing and delivering this Joinder and Amendment pursuant to (i) the Amended and Restated Registration Rights Agreement, dated as of January 23, 2018 (as the same may be amended from time to time, the ?Registration Agreement?), by and among R1 RCM Inc.,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of R1 RCM Inc. Subsidiary Jurisdiction of Organization Accretive Health Mauritius, Inc. Mauritius cGate Health, Inc. Delaware Clearsight Intermediate Holdings, Inc. Delaware Intermedix ARM, LLC Delaware Intermedix Corporation Delaware Intermedix Holdings, Inc. Delaware Intermedix Lietuva, UAB Lithuania Intermedix Midco, Inc. Delaware Intermedix Office Based, LLC Delaware

Description of Common Stock

Exhibit 4.2 Description of Registrant?s Common Stock General Under the Restated Certificate of Incorporation, as amended (the ?Charter?), of R1 RCM Inc. (the ?Company? or ?R1?), R1 is authorized to issue 500 million shares of common stock, par value $0.01 per share (the ?Common Stock?), and 5 million shares of preferred stock, par value $0.01 per share. Common Stock Voting Rights The holders of Co

Fourth Quarter and Full Year 2020 Results Conference Call February 18, 2021 Exhibit 99.2 2 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursua

Fourth Quarter and Full Year 2020 Results Conference Call February 18, 2021 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: R1 RCM Inc. Title of Class of Securities: Common Stock CUSIP Number: 749397105 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Certificate of Elimination of 8.00% Series A Convertible Preferred Stock, dated January 19, 2021

Exhibit 3.1 CERTIFICATE OF ELIMINATION of 8.00% SERIES A CONVERTIBLE PREFERRED STOCK of R1 RCM INC. Pursuant to Section 151(g) of the Delaware General Corporation Law R1 RCM Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: FIRST: That pursuant to the authority expressly vested in the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* R1 RCM INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) (CU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* R1 RCM INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00438V103 (CUSIP Number) Glenn Miller c/o TowerBrook Capital Partners L.P. Park Avenue Tower 65 East 55th Street, 19th Floor New York, NY 10022 (212) 699

Amendment No. 2 and Waiver, dated as of January 13, 2021, to Credit Agreement, by and among R1 RCM Inc., the other parties party thereto as Credit Parties (as defined therein), Bank of America N.A., as administrative agent and the financial institutions party thereto as lenders

Exhibit 10.1 Execution Version AMENDMENT NO. 2 AND WAIVER TO CREDIT AGREEMENT This AMENDMENT NO. 2 AND WAIVER (this “Amendment”) dated as of January 13, 2021 to the Credit Agreement dated as of June 26, 2019 (as amendment by the Amendment No. 1 dated as of March 20, 2020 and as further amended, restated, amended and restated, supplemented or otherwise modified prior to the Amendment No. 2 Effectiv

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Amendment to the Investor Rights Agreement, dated January 15, 2021, by and among the Partnership and the Issuer

Exhibit 7.13 AMENDMENT TO INVESTOR RIGHTS AGREEMENT This AMENDMENT to Investor Rights Agreement (this “Amendment”), dated as of January 15, 2021, is entered into by and between R1 RCM Inc., a Delaware corporation (the “Company”), and TCP-ASC ACHI Series LLLP, a Delaware limited liability limited partnership (the “Investor”). W I T N E S S E T H: WHEREAS, reference is made to that certain Investor

39th Annual J.P. Morgan Healthcare Conference January 11, 2021 Exhibit 99.1 2 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the saf

r1rcminvestorpresentatio 39th Annual J.P. Morgan Healthcare Conference January 11, 2021 Exhibit 99.1 2 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Preferred Stock Agreement, dated as of January 5, 2021, between Old R1 RCM and TCP-ASC ACHI Series LLLP (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No. 001-34746) filed on January 6, 2021)

Exhibit 10.1 Execution Version This PREFERRED STOCK AGREEMENT (this “Agreement”) dated as of January 5, 2021, is entered into by and between R1 RCM Inc., a Delaware corporation (the “Company”), and TCP-ASC ACHI Series LLLP, a Delaware limited liability limited partnership (the “Investor”). WHEREAS, the Company has issued shares of Series A Convertible Preferred Stock, par value $0.01 per share, of

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* R1 RCM INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) (CU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* R1 RCM INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00438V103 (CUSIP Number) Glenn Miller c/o TowerBrook Capital Partners L.P. Park Avenue Tower 65 East 55th Street, 19th Floor New York, NY 10022 (212) 699

Preferred Stock Agreement, dated January 5, 2021, among the Partnership and the Issuer

Exhibit 7.12 This PREFERRED STOCK AGREEMENT (this “Agreement”) dated as of January 5, 2021, is entered into by and between R1 RCM Inc., a Delaware corporation (the “Company”), and TCP-ASC ACHI Series LLLP, a Delaware limited liability limited partnership (the “Investor”). WHEREAS, the Company has issued shares of Series A Convertible Preferred Stock, par value $0.01 per share, of the Company (“Ser

R1 RCM Announces Conversion Agreement with Ascension and TowerBrook Conversion of Preferred Stock to Shares of Common Stock to Enhance Alignment with Common Shareholders Ascension and TowerBrook Committed to Supporting Sustainable Long-Term Growth

Exhibit 99.1 R1 RCM Announces Conversion Agreement with Ascension and TowerBrook Conversion of Preferred Stock to Shares of Common Stock to Enhance Alignment with Common Shareholders Ascension and TowerBrook Committed to Supporting Sustainable Long-Term Growth CHICAGO, IL – January 6, 2021 – R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to he

Form of Amendment to Investor Rights Agreement between R1 RCM Inc. and TCP-ASC ACHI Series LLLP.

Exhibit 4.1 AMENDMENT TO INVESTOR RIGHTS AGREEMENT This AMENDMENT to Investor Rights Agreement (this “Amendment”), dated as of [●], 2021, is entered into by and between R1 RCM Inc., a Delaware corporation (the “Company”), and TCP-ASC ACHI Series LLLP, a Delaware limited liability limited partnership (the “Investor”). W I T N E S S E T H: WHEREAS, reference is made to that certain Investor Rights A

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Exhibit 99.2 Third Quarter 2020 Results Conference Call November 3, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe har

r1rcmq32020earningspptv3 Exhibit 99.2 Third Quarter 2020 Results Conference Call November 3, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past

R1 RCM Reports Third Quarter 2020 Results

Exhibit 99.1 R1 RCM Reports Third Quarter 2020 Results CHICAGO - November 3, 2020 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months ended September 30, 2020. Third Quarter 2020 Results: •Revenue of $307.2 million, up $6.0 million and 2.0% compared to the same period last year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-34746 R1 RC

RCM / R1 RCM Inc. / TCP-ASC ACHI Series LLLP - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* R1 RCM INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00438V103 (CUSIP Number) Glenn Miller c/o TowerBrook Capital Partners L.P. Park Avenue Tower 65 East 55th Street, 19th Floor New York, NY 10022 (212) 699-

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-34746 R1 RCM INC

and Rachel Wilson dated April 29, 2020 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-34746) filed on August 5, 2020)

Exhibit 10.1 R1 RCM Inc. 401 N Michigan Avenue, Suite 2700 Chicago, IL 60611 April 29, 2020 Re: Employment Terms Dear Rachel: On behalf of R1 RCM Inc. (“R1”), I am delighted to confirm our offer to you to join R1 as Chief Financial Officer and Treasurer, reporting to R1’s Chief Executive Officer. Your start date will be June 1, 2020 and your position will be located at R1’s Chicago, Illinois headq

Addendum No. 7 to Amended and Restated Services Agreement between the Registrant and IHC Health Services, Inc. dated as of April 30, 2020

Exhibit 10.2 ADDENDUM NO. 7 TO AMENDED AND RESTATED SERVICES AGREEMENT This Addendum No. 7 (this “Addendum”) is made and entered into as of the 30th day of April, 2020 (the “Addendum Effective Date”) by and between IHC Health Services, Inc., a Utah non-profit corporation, (“IMH” or sometimes referred to as “Intermountain” or “Intermountain Healthcare”) and R1 RCM Inc., a Delaware corporation, form

R1 RCM Reports Second Quarter 2020 Results

Exhibit 99.1 R1 RCM Reports Second Quarter 2020 Results CHICAGO - August 4, 2020 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months ended June 30, 2020. Second Quarter 2020 Results: •Revenue of $314.7 million, up $19.7 million and 6.7% compared to the same period last year •GA

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

Exhibit 99.2 Second Quarter 2020 Results Conference Call August 4, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harb

r1rcmq22020earningsppt Exhibit 99.2 Second Quarter 2020 Results Conference Call August 4, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past, e

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Exhibit 99.1 Investor Presentation July 20, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Pr

july2020investorpresenta Exhibit 99.1 Investor Presentation July 20, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past, events and often addre

Form of Grant of Performance-Based Restricted Stock Unit Awards Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No. 001-34746) filed on July 15, 2020)

Exhibit 10.1 GRANT OF PERFORMANCE BASED AWARDS PURSUANT TO THE R1 RCM INC. SECOND AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN * * * * * Participant: [NAME] Grant Date: [GRANT DATE] Number of PBRSUs: [NUMBER OF PBRSUs] Measurement Date: [MEASUREMENT DATE] (the “Non-COC Measurement Date”) * * * * * THIS GRANT OF PERFORMANCE BASED AWARDS (this “Agreement”), dated as of the Grant Date specified abo

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On April 1, 2020, R1 RCM Inc. (the “Company” or “R1”) completed the acquisition of scheduling.com, Inc. d/b/a SCI Solutions, Inc. (“SCI”) pursuant to a stock purchase agreement dated as of January 9, 2020 (“the Stock Purchase Agreement”), by and among the Company, Clearsight Intermediate Holdings, Inc. (“Clearsight Holdings”

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

CONSOLIDATED FINANCIAL STATEMENTS Clearsight Intermediate Holdings, Inc. Year Ended December 31, 2019 With Report of Independent Auditors Clearsight Intermediate Holdings, Inc. Consolidated Financial Statements Year Ended December 31, 2019

Exhibit 99.1 CONSOLIDATED FINANCIAL STATEMENTS Clearsight Intermediate Holdings, Inc. Year Ended December 31, 2019 With Report of Independent Auditors Clearsight Intermediate Holdings, Inc. Consolidated Financial Statements Year Ended December 31, 2019 Contents Report of Independent Auditors 1 Consolidated Financial Statements Consolidated Balance Sheet 3 Consolidated Statement of Change in Stockh

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On April 1, 2020, R1 RCM Inc. (the “Company” or “R1”) completed the acquisition of scheduling.com, Inc. d/b/a SCI Solutions, Inc. (“SCI”) pursuant to a stock purchase agreement dated as of January 9, 2020 (“the Stock Purchase Agreement”), by and among the Company, Clearsight Intermediate Holdings, Inc. (“Clearsight Holdings”

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Exhibit 99.1 Investor Presentation June 3, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Pri

june2020investorpresenta Exhibit 99.1 Investor Presentation June 3, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past, events and often addres

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Exhibit 99.2 First Quarter 2020 Results Conference Call May 5, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor p

r1rcmq12020earningsprese Exhibit 99.2 First Quarter 2020 Results Conference Call May 5, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past, eve

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

Addendum No. 6 to Amended and Restated Services Agreement between the Registrant and IHC Health Services, Inc. dated as of January 28, 2020

Exhibit 10.2 ADDENDUM NO. 6 TO AMENDED AND RESTATED SERVICES AGREEMENT This Addendum No. 6 (this “Addendum”) is made and entered into as of the 28 day of January, 2020 (the “Addendum Effective Date”) by and between IHC Health Services, Inc., a Utah non-profit corporation, (“IMH” or sometimes referred to as “Intermountain” or “Intermountain Healthcare”) and R1 RCM Inc., a Delaware corporation, form

R1 RCM Reports First Quarter 2020 Results

Exhibit 99.1 R1 RCM Reports First Quarter 2020 Results CHICAGO - May 5, 2020 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months ended March 31, 2020. First Quarter 2020 Results: •Revenue of $320.5 million, up $44.6 million and 16.2% compared to the same period last year •GAAP

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-34746 R1 RCM IN

R1 RCM Appoints Rachel Wilson as Executive Vice President and Chief Financial Officer

Exhibit 99.1 R1 RCM Appoints Rachel Wilson as Executive Vice President and Chief Financial Officer CHICAGO – May 4, 2020 – R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management (RCM) services to healthcare providers, today announced the appointment of Rachel Wilson as Executive Vice President, Chief Financial Officer and Treasurer effective June 1, 2020. Wils

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

RCM / R1 RCM Inc. DEF 14A - - DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State

Regulation FD Disclosure, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

R1 Completes Acquisition of SCI Solutions

Exhibit 99.1 R1 Completes Acquisition of SCI Solutions CHICAGO – April 1, 2020 – R1 RCM Inc. (NASDAQ:RCM), a leader in technology-enabled revenue cycle management (RCM) services to healthcare providers, today announced it has completed the acquisition of SCI Solutions, Inc. (SCI). The combination of R1 and SCI is expected to deliver enhanced value for healthcare providers by enabling them to expan

Amendment No. 1 to Credit Agreement, dated as of March 20, 2020, by and among R1 RCM Inc., the other parties party thereto as Credit Parties (as defined therein), Bank of America, N.A., as administrative agent and the financial institutions party thereto as lenders.

Exhibit 10.1 Execution Verison AMENDMENT NO. 1 TO CREDIT AGREEMENT This AMENDMENT NO. 1 (this “Amendment”) dated as of March 20, 2020 to the Credit Agreement dated as of June 26, 2019 (as amended, supplemented or otherwise modified prior to the Amendment No. 1 Effective Date (as defined below), the “Credit Agreement”), among R1 RCM Inc., a Delaware corporation (the “Borrower”), the other Credit Pa

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

and Ascension Health dated as of December 20, 2019 (incorporated by reference to Exhibit 10.61 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (File No. 001-34746) filed on February 20, 2020)

Exhibit 10.61 AMENDMENT NO. 4 TO AMENDED AND RESTATED MASTER PROFESSIONAL SERVICES AGREEMENT BY AND BETWEEN ASCENSION HEALTH AND R1 RCM INC. This Amendment No. 4 to the Master Professional Services Agreement (this “Amendment”) by and between Ascension Health (“Ascension Health”) and R1 RCM Inc. (formerly known as Accretive Health, Inc.) (“R1”) is entered into effective this 20th day of December, 2

R1 RCM Reports Fourth Quarter and Full Year 2019 Results

EX-99.1 2 a2019pressrelease.htm EXHIBIT 99.1 Exhibit 99.1 R1 RCM Reports Fourth Quarter and Full Year 2019 Results CHICAGO - February 20, 2020 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months and year ended December 31, 2019. Fourth Quarter 2019 Results: • Revenue of $314.0

Description of Common Stock

Exhibit 4.2 Description of Registrant’s Common Stock General Under the Restated Certificate of Incorporation, as amended (the “Charter”) of R1 RCM Inc. (the “Company” or “R1”), R1 is authorized to issue 500 million of shares of common stock, par value $0.01 per share (the “Common Stock”), and 5 million shares of preferred stock, par value $0.01 per share. Of its authorized preferred stock, R1 has

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34746 R1 RCM Inc. (Exact name of

Amendment No. 5 to Amended and Restated Services Agreement between the Registrant and IHC Health Services, Inc. dated as of December 31, 2019

Exhibit 10.62 ADDENDUM NO. 5 TO AMENDED AND RESTATED SERVICES AGREEMENT This Addendum No. 5 (this “Addendum”) is made and entered into as of the 31 day of December, 2019 (the “Addendum Effective Date”) by and between IHC Health Services, Inc., a Utah non-profit corporation, (“IMH” or sometimes referred to as “Intermountain” or “Intermountain Healthcare”) and R1 RCM Inc., a Delaware corporation, fo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Exhibit 99.2 Fourth Quarter and Full Year 2019 Results Conference Call February 20, 2020 Forward‐Looking Statements and Non‐GAAP Financial Measures This presentation includes information that may constitute “forward‐looking statements,” made pursuant

q42019earningspresentati Exhibit 99.2 Fourth Quarter and Full Year 2019 Results Conference Call February 20, 2020 Forward‐Looking Statements and Non‐GAAP Financial Measures This presentation includes information that may constitute “forward‐looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward‐looking statements relate to

ACHI / Accretive Health, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* R1 RCM INC. (Name of Issuer) Common Stock (Title of Class of Securities) 749397105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

R1 Announces Agreement to Acquire SCI Solutions, a Leading Provider of Digital Patient Engagement Solutions Acquisition adds robust digital front door capabilities to R1’s technology platform, enabling healthcare providers to automate ordering, sched

Exhibit 99.1 R1 Announces Agreement to Acquire SCI Solutions, a Leading Provider of Digital Patient Engagement Solutions Acquisition adds robust digital front door capabilities to R1’s technology platform, enabling healthcare providers to automate ordering, scheduling, and authorization processes CHICAGO - January 13, 2020 - R1 RCM Inc. (NASDAQ:RCM), a leader in technology-enabled revenue cycle ma

Exhibit 99.2 38th Annual J.P. Morgan Healthcare Conference January 15, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes statements that may constitute “forward-looking statements” made pursuant to the safe ha

jpmorganpresentation1152 Exhibit 99.2 38th Annual J.P. Morgan Healthcare Conference January 15, 2020 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes statements that may constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In particular, statements about future events and re

Stock Purchase Agreement, dated as of January 9, 2020, by and among the Registrant, Clearsight Intermediate Holdings, Inc. and Clearsight Group Holdings, LLC (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K (file No. 001-34746) filed on January 13, 2020) (Exhibits and schedules were omitted pursuant to Item 601(b)(2) of Regulation S-K and will be furnished to the Securities and Exchange Commission upon request)

Exhibit 2.1 EXECUTION STOCK PURCHASE AGREEMENT by and among CLEARSIGHT INTERMEDIATE HOLDINGS, INC. CLEARSIGHT GROUP HOLDINGS, LLC and R1 RCM Inc. Dated as of January 9, 2020 33067829.14 TABLE OF CONTENTS Page ARTICLE 1 PURCHASE AND SALE OF THE STOCK 1 1.1 Purchase and Sale of Stock 1 1.2 Purchase Price 1 1.3 The Closing 2 1.4 The Closing Transactions 2 1.5 Purchase Price Adjustments 3 1.6 Earn-Out

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

Exhibit 99.1 Investor Presentation December 27, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of th

investorpresentationdec2 Exhibit 99.1 Investor Presentation December 27, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past, events and often a

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number)

RCM / R1 RCM Inc. / TOLAN MARY A - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* R1 RCM, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 00438V103 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the

Exhibit 99.2 Third Quarter 2019 Results Conference Call November 5, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe har

q319earningspresentation Exhibit 99.2 Third Quarter 2019 Results Conference Call November 5, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

R1 RCM Reports Third Quarter 2019 Results

Exhibit 99.1 R1 RCM Reports Third Quarter 2019 Results CHICAGO - November 5, 2019 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months ended September 30, 2019. Third Quarter 2019 Results: • Revenue of $301.2 million, up $50.8 million and 20.3% compared to the same period last y

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-34746 R1 RC

EX-24

EXHIBIT 24 LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents that the undersigned hereby makes, constitutes and appoints each of Richard B.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number)

R1 RCM Appoints Richard Evans as Interim CFO Follows Resignation of Christopher Ricaurte Raises 2019 Adjusted EBITDA Outlook

EX-99.1 Exhibit 99.1 R1 RCM Appoints Richard Evans as Interim CFO Follows Resignation of Christopher Ricaurte Raises 2019 Adjusted EBITDA Outlook CHICAGO, September 24, 2019 – R1 RCM Inc. (NASDAQ:RCM), a leader in technology-enabled revenue cycle management (RCM) services to healthcare providers, today announced that its Board of Directors has appointed Richard B. Evans, Jr., Corporate Controller

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

Exhibit 99.2 Second Quarter 2019 Results Conference Call August 6, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harb

q219earningspresentation Exhibit 99.2 Second Quarter 2019 Results Conference Call August 6, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past,

R1 RCM Reports Second Quarter 2019 Results

Exhibit 99.1 R1 RCM Reports Second Quarter 2019 Results CHICAGO - August 6, 2019 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months ended June 30, 2019. Second Quarter 2019 Results: • Revenue of $295.0 million, up $87.1 million and 41.9% compared to the same period last year •

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

Addendum No. 4 to the Amended and Restated Services Agreement between the Registrant and IHC Health Services, Inc. dated as of April 30, 2010 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (file No. 001-34746) filed on August 6, 2019)

Exhibit 10.1 [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. ADDENDUM NO. 4 TO AMENDED AND RESTATED SERVICES AGREEMENT This Addendum No. 4 (this “Addendum”) is made and entered into as of the 30th day of April, 2019 (the “Addendum Effective Date”) by and be

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-34746 R1 RCM INC

RCM / R1 RCM Inc. / TCP-ASC ACHI Series LLLP - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* R1 RCM INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00438V103 (CUSIP Number) Glenn Miller c/o TowerBrook Capital Partners L.P. Park Avenue Tower 65 East 55th Street, 27th Floor New York, NY 10022 (212) 699-

Credit Agreement, dated as of June 26, 2019, by and among the Registrant, the other parties party thereto as Credit Parties (as defined therein), Bank of America, N.A., as administrative agent and the financial institutions party thereto as lenders (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (file No.001-34746) filed on June 26, 2019)

Exhibit 10.1 Execution Version $425,000,000 CREDIT AGREEMENT Dated as of June 26, 2019 by and among R1 RCM INC., as the Borrower, THE OTHER PERSONS PARTY HERETO THAT ARE DESIGNATED AS CREDIT PARTIES, BANK OF AMERICA, N.A., as Agent for all Lenders, THE OTHER FINANCIAL INSTITUTIONS PARTY HERETO as Lenders, and BOFA SECURITIES, INC., JPMORGAN CHASE BANK, N.A., WELLS FARGO BANK, NATIONAL ASSOCIATION,

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

R1 RCM Reports First Quarter 2019 Results

Exhibit 99.1 R1 RCM Reports First Quarter 2019 Results CHICAGO - May 9, 2019 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months ended March 31, 2019. First Quarter 2019 Results: • Revenue of $275.9 million, up $128.6 million and 87.3% compared to the same period last year • GA

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

Exhibit 99.2 First Quarter 2019 Results Conference Call May 9, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor p

q119earningspresentation Exhibit 99.2 First Quarter 2019 Results Conference Call May 9, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past, eve

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-34746 R1 RCM IN

and Joseph Flanagan (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-34746) filed on May 9, 2019)

Exhibit 10.1 R1 RCM Inc. 401 N Michigan Avenue, Suite 2700 Chicago, IL 60611 March 6, 2019 Mr. Joseph Flanagan Re: Amendment No. 2 to Offer Letter Dear Joe: Reference is hereby made to that certain letter agreement by and between you and R1 RCM Inc. (the “Company”) dated April 27, 2013 (the “Letter Agreement”), as amended by that certain amendment dated April 29, 2014 (the “Amendment”). The Letter

RCM / R1 RCM Inc. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State

R1 Announces Appointment of Jill Smith to Board of Directors

Exhibit 99.1 R1 Announces Appointment of Jill Smith to Board of Directors • Charles Ditkoff Announces Decision to Retire from Board at Annual Meeting CHICAGO – April 16, 2019 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced the appointment of Jill Smith, CEO of Allied Minds (LSE: ALM), to the company’s

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

Form of Grant of Performance-Based Restricted Stock Unit Awards Agreement pursuant to the Second Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (file No. 001-34746) filed on April 10, 2019)

Exhibit 10.1 GRANT OF PERFORMANCE BASED AWARDS PURSUANT TO THE R1 RCM INC. SECOND AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN * * * * * Participant: [NAME] Grant Date: [GRANT DATE] Number of PBRSUs: [NUMBER OF PBRSUs] Measurement Date: [MEASUREMENT DATE] (the “Non-COC Measurement Date”) * * * * * THIS GRANT OF PERFORMANCE BASED AWARDS (this “Agreement”), dated as of the Grant Date specified abo

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Exhibit 99.2 Fourth Quarter and Full Year 2018 Results Conference Call February 22, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward‐looking statements,” made pursuant

q418earningspresentation Exhibit 99.2 Fourth Quarter and Full Year 2018 Results Conference Call February 22, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward‐looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward‐looking statements relate to

R1 RCM Reports Fourth Quarter and Full Year 2018 Results

Exhibit 99.1 R1 RCM Reports Fourth Quarter and Full Year 2018 Results CHICAGO - February 22, 2019 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months and year ended December 31, 2018. Fourth Quarter 2018 Results: • Revenue of $262.9 million, up $122.6 million and 87.4% compared

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of R1 RCM Inc. Subsidiary Jurisdiction of Organization Accretive Health Mauritius, Inc. Mauritius Advanced Data Processing, Inc. Delaware Intermedix Analytics, LLC Delaware Intermedix ARM, LLC Delaware Intermedix Corporation Delaware Intermedix Holdings, Inc. Delaware Intermedix Lietuva, UAB Lithuania Intermedix Midco, Inc. Delaware Intermedix Office Based, LLC Delaware I

Addendum No. 3 to Amended and Restated Services Agreement between the Registrant and IHC Health Services, Inc. dated as of October 1, 2018 (incorporated by reference to Exhibit 10.72 to Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (file No. 001-34746) filed on February 22, 2019)

Exhibit 10.72+ ADDENDUM NO. 3 TO AMENDED AND RESTATED SERVICES AGREEMENT This Addendum No. 3 (this "Addendum") is made and entered into as of the 1st day of October, 2018 (the "Addendum Effective Date") by and between IHC Health Services, Inc., a Utah non-profit corporation, ("IMH" or sometimes referred to as "Intermountain" or "Intermountain Healthcare") and R1 RCM Inc., a Delaware corporation, f

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34746 R1 RCM Inc. (Exact name of

ACHI / Accretive Health, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* R1 RCM INC. (Name of Issuer) Common Stock (Title of Class of Securities) 749397105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

ACHI / Accretive Health, Inc. / CLINE J MICHAEL - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* R1 RCM Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 749397105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

37th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisi

exhibit99 37th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past, events and often address

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

Exhibit 99.2 Third Quarter 2018 Results Conference Call November 7, 2018 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe har

q318earningspresentation Exhibit 99.2 Third Quarter 2018 Results Conference Call November 7, 2018 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not past

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2018 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

R1 RCM Reports Third Quarter 2018 Results

Exhibit 99.1 R1 RCM Reports Third Quarter 2018 Results CHICAGO - November 7, 2018 - R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months ended September 30, 2018. Third Quarter 2018 Results: • GAAP net services revenue of $250.4 million, up $127.2 million compared to the same peri

RCM / R1 RCM Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-34746 R1 RC

Amendment No. 3 to Amended and Restated Master Professional Services Agreement between the Registrant and Ascension Health dated as of July 5, 2018 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on 10-Q (file No. 001-34746) filed on November 7, 2018)

Exhibit 10.1 AMENDMENT NO. 3 TO AMENDED AND RESTATED MASTER PROFESSIONAL SERVICES AGREEMENT BY AND BETWEEN ASCENSION HEALTH AND R1 RCM INC. This Amendment No. 3 to the Master Professional Services Agreement (this “Amendment”) by and between Ascension Health (“Ascension Health”) and R1 RCM Inc. (formerly known as Accretive Health, Inc.) (“R1”) is entered into effective this 5th day of July, 2018 (t

Other Events

Document

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2018 R1 RCM Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34746 02-0698101 (State or Other Jurisdiction of Incorporation) (Commission File Number)